- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03462043
A Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
November 20, 2018 updated by: NeuroDerm Ltd.
A Pivotal, Open-Label, Randomized, Crossover Study in Patients With Advanced Parkinson's Disease to Assess the Relative Bioavailability of Levodopa Administered as ND0612 Subcutaneous Infusion Versus Levodopa Administered as Carbidopa-Levodopa Enteral Suspension
This study will assess the relative bioavailability of s.c.
infused ND0612 versus jejunally infused CLES in patients with advanced PD.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
This study will be an open-label, randomized, crossover study to assess the relative bioavailability of s.c.
infused ND0612 versus jejunally infused CLES in patients with advanced PD.
Study Type
Interventional
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Roma, Italy, 00163
- 91601
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patients with Advanced PD treated with LD/CD at a dose of at least 800 mg LD
- Female patients must have a negative pregnancy test at screening and at admission.
- Patients must have a body mass index (BMI) within the range of 18.5 - 35 kg/m2, where BMI = body weight (kg) / height (m2) at screening.
- Must be willing and able to communicate and participate in the whole study.
- Must provide written informed consent.
- Must agree to use an adequate method of contraception (per local independent ethics committee requirements).
- Area of administration to be evaluable for local skin reaction (normal skin without skin burns, scars or large tattoos in the area of administration
Exclusion Criteria:
- Any relevant medical, surgical, or psychiatric condition, laboratory value, or concomitant medication which, in the opinion of the Investigator, makes the patient unsuitable for study entry or potentially unable to complete all aspects of the study.
- Positive serum serology for Hepatitis B Virus (HBV), Hepatitis C Virus (HCV) or Human Immunodeficiency Virus (HIV) at the screening visit.
- Patients with a history of drug abuse or alcoholism within the past 12 months prior to screening or positive drugs of abuse or alcohol test result at the screening visit and/or on admission.
- Clinically significant electrocardiogram (ECG) rhythm abnormalities.
- Renal or liver dysfunction that may alter drug metabolism including: serum creatinine >1.5 mg/dL, serum aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2 x upper limit of normal (ULN), total serum bilirubin >2.5 mg/dL.
- Psychiatric, neurological or behavioral disorders that may interfere with the conduct or interpretation of the study, including dementia, or patients who are considered to be violent or at suicidal risk by the Investigator.
- Blood loss of greater than 500 mL within the previous 3 months prior to first dosing.
- use of any medication from the prohibited concomitant therapies
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Sequence A
|
s.c. infused
Carbidopa-Levodopa Enteral Suspension.
|
Active Comparator: Sequence B
|
s.c. infused
Carbidopa-Levodopa Enteral Suspension.
|
Active Comparator: Sequence C
|
s.c. infused
Carbidopa-Levodopa Enteral Suspension.
|
Active Comparator: Sequence D
|
s.c. infused
Carbidopa-Levodopa Enteral Suspension.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Bioavailability
Time Frame: 6-7 days
|
To assess relative bioavailability of levodopa (LD) administered as ND0612, infused subcutaneously (s.c.), versus LD administered as carbidopa-levodopa enteral suspension (CLES)
|
6-7 days
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Osnat Ehrman, NeuroDerm Ltd.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 10, 2018
Primary Completion (Anticipated)
November 20, 2018
Study Completion (Anticipated)
December 30, 2018
Study Registration Dates
First Submitted
March 6, 2018
First Submitted That Met QC Criteria
March 9, 2018
First Posted (Actual)
March 12, 2018
Study Record Updates
Last Update Posted (Actual)
November 23, 2018
Last Update Submitted That Met QC Criteria
November 20, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- ND0612-315
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Parkinson
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedParkinson Disease 6, Early-Onset | Parkinson Disease (Autosomal Recessive, Early Onset) 7, Human | Parkinson Disease Autosomal Recessive, Early Onset | Parkinson Disease, Autosomal Recessive Early-Onset, Digenic, Pink1/Dj1United States
-
ProgenaBiomeRecruitingParkinson Disease | Parkinsons Disease With Dementia | Parkinson-Dementia Syndrome | Parkinson Disease 2 | Parkinson Disease 3 | Parkinson Disease 4United States
-
Bial - Portela C S.A.Completed
-
Abbott Medical DevicesBaylor College of Medicine; University of HoustonCompleted
-
Mayo ClinicCompleted
-
King's College LondonGlaxoSmithKlineCompletedParkinson Disease | Idiopathic Parkinson Disease | Parkinson Disease, PARK8United Kingdom
-
Beijing Pins Medical Co., LtdUnknownIdiopathic Parkinson PatientsChina
-
National Yang Ming UniversityUnknownEarly Onset Parkinson Disease | Early Stage Parkinson Disease
-
Ohio State UniversityCompletedParkinson's Disease | Parkinson Disease | Idiopathic Parkinson Disease | Idiopathic Parkinson's Disease | Parkinson Disease, Idiopathic | Parkinson's Disease, IdiopathicUnited States
-
Mahatma Gandhi Institute of Medical SciencesCompletedStroke, Parkinson' s Disease, Neurological Impairments, Tele-rehabilitationIndia
Clinical Trials on ND0612
-
NeuroDerm Ltd.Active, not recruitingParkinson's DiseaseUnited States, Spain, Austria, Czechia, France, Poland, Germany, Israel, Italy
-
NeuroDerm Ltd.Completed
-
NeuroDerm Ltd.CompletedParkinson's DiseaseUnited States, Israel, Italy, Austria
-
NeuroDerm Ltd.Michael J. Fox Foundation for Parkinson's ResearchCompletedParkinson's DiseaseIsrael
-
NeuroDerm Ltd.Quotient ClinicalCompletedParkinson's DiseaseUnited Kingdom
-
NeuroDerm Ltd.Active, not recruitingParkinson's DiseaseUnited States, Israel, Spain, France, Russian Federation, Austria, Italy, Belgium, Czechia, Hungary, Netherlands, Poland, Portugal, Slovakia, Ukraine, United Kingdom